The Latest Breaking News from Eli Lilly and Company

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….

As the CFO role continues to evolve, the leaders also explained the integral part of being an effective finance chief.

Zepbound is expected to be available in the U.S. by the end of the year.

Drugmaker Eli Lilly and Company (LLY) is scheduled to release its third-quarter results soon. While its revenue is expected to rise sharply over the prior-year quarter, its earnings are expected to decline. So, how should investors position themselves before the results are out? Read on to learn more….

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.